Figure 5.
In-vivo absorption studies. (A) Changes in plasma levels of PGE1 after administration of plain PGE1 (80 μg/kg) via the intravenous and pulmonary routes (n=6, modified from Gupta et al., 2010), and (B) In-vivo performances of the formulations (PEI-1, and PEI-4) after pulmonary administration of PGE1 (120 μg/kg). Data represent the mean ± standard deviation (n=6–8).